THG shares jump 7% as Q1 revenue growth hits post-pandemic high

THG reported 7% constant-currency Q1 revenue growth to £393.1 million, its strongest first-quarter performance since the pandemic, with Beauty revenue at £233.3 million and Nutrition at £159.8 million. The company reiterated full-year 2026 guidance for 4.8% revenue growth, £100 million adjusted EBITDA and £38 million underlying free cash flow, while Jefferies kept a buy rating and 60p target. Shares rose more than 7% on the update, though reported growth was partially diluted by disposals and discontinued activities.

Analysis

This print is less about a one-quarter beat and more about evidence that THG has finally found a cleaner growth engine after years of mixed quality revenue. The most important second-order effect is mix: the licensed-out nutrition categories and higher-margin adjacencies reduce working capital intensity and should support cash conversion even if reported growth normalizes. That matters because the market has historically discounted THG for growth that did not translate into durable free cash flow; a three-year best cash flow quarter is the first real rebuttal to that narrative.

The competitive read-through is also broader than THG itself. Better demand in prestige beauty and US dermocosmetics suggests the consumer is still trading toward specialized, higher-conviction purchases rather than broad basket fatigue, which is a mild positive for niche beauty operators and a warning for generalized mass-market retailers. Flex at checkout is more interesting as a distribution wedge than as a revenue driver: if HSA/FSA payment rails materially lift conversion in skincare/wellness, that creates a low-cost customer acquisition advantage that larger incumbents will need months to replicate.

The main risk is that investors anchor on reported growth while underestimating how much of the quarter was helped by mix, licensing, and category rotation rather than core organic acceleration. Whey inflation is the key margin variable over the next 1-2 quarters; if input costs stay elevated while promotional intensity rises, EBITDA leverage could disappoint even with steady top-line momentum. The bigger contrarian question is whether the market is still too skeptical: a rerating may be justified if management can show two more quarters of cash conversion, but a single clean quarter is not enough to erase execution risk.

For competitors, the signal is that premium beauty and nutrition brands with strong direct-to-consumer data can still win share without relying on broad discounting, which should pressure weaker third-party resellers and undifferentiated private-label players. The licensing strategy also implies THG is willing to sacrifice some headline growth for asset-light economics, a move that could compress near-term reported revenue but improve long-run ROIC. That is usually a favorable setup for equity holders if the market is still valuing the company on sales multiple rather than cash generation.

Key Decisions for Investors

• Long THG (LON:THG) for 1-3 months on any post-rally pullback: thesis is cash-flow inflection plus mix improvement; risk is that a single strong quarter proves transitory. Use a tight stop if the stock fails to hold the post-earnings gap.
• Pair trade: long THG (LON:THG) / short a weaker European online retail basket over 6-12 weeks. The relative edge is asset-light category mix and improving cash conversion; downside is broad consumer momentum fades and the pair mean-reverts.
• Buy FLEX on a 3-6 month horizon as a thematic beneficiary of HSA/FSA-enabled checkout adoption in consumer health and beauty. Risk/reward works if payment-rail partnerships scale across other merchants; downside is the feature remains niche and non-recurring.
• Short high-burn, low-margin e-commerce names against THG if you want a cleaner expression of the thesis. THG’s improving free cash flow makes it a quality relative-value long versus structurally lossmaking peers.
• If managing event risk, consider a call spread in THG into the next quarter rather than outright equity. The setup is asymmetric if cash flow stays strong, but the upside can be capped if the market decides the beat was mostly mix-driven.